RESUMO
AIMS: Guidelines differ in their recommendations on therapy to prevent gastrointestinal bleeding for patients treated with dual antiplatelet treatment (DAPT). We sought to investigate the effectiveness of proton pump inhibitors (PPIs) to prevent upper gastrointestinal (UGI) bleeding in patients using DAPT following myocardial infarction (MI) in relation to current European Society of Cardiology guidelines recommendations. METHODS AND RESULTS: We linked Danish nationwide registries to identify patients taking DAPT 7 days following hospital discharge for an acute MI, and excluded individuals on anticoagulation therapy. We used multiple Cox regression modelling, to compute average risk of UGI bleeding in relation to PPI use. The associated treatment efficacy was compared based on guideline risk assessment. We studied 46 301 patients on DAPT after MI. Only 35% of patients at higher risk of UGI bleeding received recommended treatment with a PPI based on the guideline criteria. The 1--year risk of UGI bleeding was 1.0% [95% confidence interval (CI) 0.9-1.1%] and 1.7% (CI 1.5-2.0%) for high-risk patients. Overall PPI compared with no therapy, was associated with a risk ratio for UGI bleeding of 0.62 (CI 0.48-0.77) corresponding to an absolute risk difference of 0.44% (CI 0.39-0.48%). Proton pump inhibitor therapy was associated with a similar absolute risk difference [0.47% (CI 0.43-0.51%)] for high-risk patients. CONCLUSION: Proton pump inhibitor therapy is used less than suggested by guidelines in patients treated with DAPT following MI and was generally associated with reduced risk of UGI bleeding. Considering the overall low risk of bleeding, more focus should be on identifying patients benefiting the most from PPI therapy.
Assuntos
Terapia Antiplaquetária Dupla/efeitos adversos , Hemorragia Gastrointestinal/prevenção & controle , Infarto do Miocárdio/tratamento farmacológico , Inibidores da Bomba de Prótons/uso terapêutico , Doença Aguda , Idoso , Idoso de 80 Anos ou mais , Cardiologia/organização & administração , Estudos de Casos e Controles , Dinamarca/epidemiologia , Europa (Continente) , Feminino , Hemorragia Gastrointestinal/induzido quimicamente , Humanos , Masculino , Pessoa de Meia-Idade , Guias de Prática Clínica como Assunto , Valor Preditivo dos Testes , Sistema de Registros , Medição de Risco , Resultado do TratamentoRESUMO
Since the introduction of the ad modum Branemark prototype prosthesis for the mandibular edentulous patient more than 30 years ago, design permutations have met clinician and patient considerations. Dental student training and specialist continuing education often rely on anecdotal reports of success to determine the recommended design for patients. Decision-making algorithms for treatment are optimally predicated on the best available evidence. The purpose of this article is to elucidate the benefit/risk calculus of various implant modalities for the mandibular edentulous patient.